Report
FREE
• Rakovina has a portfolio of three DNA Damage Response Inhibitor drug candidates that address specific shortcomings of existing treatments.
• Rakovina’s lead kt-3000 program is designed to inhibit both PARP and HDAC enzymes; the candidate is expected to begin human trials in H1/24.
• RKV’s management team and partnership with UBC far exceed what we would expect from a
RKV: A Catalyst Heavy Oncology Story
What you need to know:• Rakovina has a portfolio of three DNA Damage Response Inhibitor drug candidates that address specific shortcomings of existing treatments.
• Rakovina’s lead kt-3000 program is designed to inhibit both PARP and HDAC enzymes; the candidate is expected to begin human trials in H1/24.
• RKV’s management team and partnership with UBC far exceed what we would expect from a
Underlying
RAKOVINA THERAPEUTICS INC
Provider
Atrium Research Corporation
Atrium Research provides institutional quality issuer paid research on North American public equities using deep fundamental analysis. Our research reports are disseminated through Bloomberg, FactSet, Capital IQ, Reuters and many more, as well as through our social media and email distribution lists.
Nicholas Cortellucci, CFA
Other Reports on these Companies
Other Reports from Atrium Research Corporation
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.